CALGARY, ALBERTA -- (Marketwire) -- 11/12/09 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT") announced that Dr. Allen Davidoff, Vice President of Product Development, will be presenting at the 2009 Neural Regeneration Workshop taking place in Albuquerque, New Mexico at the Sandia National Laboratories, a U.S. Government facility. Dr. Davidoff will be discussing "A drug based approach to Neurogenesis and recovery after acute neurologic injury".

Dr. Alan Moore, President and CEO of SCT, commented as follows:

"One of the key objectives of this workshop series is to discover treatments that restore lost or damaged brain tissue in order to support function recovery, specifically relating to traumatic brain injury developed in combat. We feel this is an ideal platform to discuss just how our stroke and traumatic brain injury regimens have the capability to regenerate brain tissue and return functionality."

About the November 2009 Neural Restoration Workshop Series: Sandia National Laboratories and the Center for Neurotechnology Studies of the Potomac Institute for Policy Studies will be hosting a workshop series to gather information on the restoration of neural function through treatments involving replacement of injured and diseased brain tissue. Two parallel workshops are being be held, the first was in Washington DC on November 4, 2009; and the second in Albuquerque, NM on November 12, 2009. The objective of these workshops is to assess the scientific and technical state-of-the-art treatments and chart a path of research and development leading to innovation in the treatment of brain injury and disease through restoration of neural tissue.

Existing treatment options focus largely upon return to function by adapting existing brain tissue to the best extent possible. Yet, none of the current treatment options seek to restore lost or damaged tissue to enable a return to function. There have been substantial advances across various disciplines that offer the potential for major innovations in the treatment of brain injury and disease, and that focused research and development may result in significant progress in this field.

In light of this, the goals of these workshops are to: (a) pulse researchers from academia, industry and government to determine the state of the art in the differentiation of neural cell types, cultivation of neural tissue, neural circuit engineering, integration of transplanted tissue with functional circuits, and mechanisms for promoting functional recovery of injured or diseased brain tissue; (b) identify key scientific and technical gaps and/or limitations; and (c) delineate opportunities for advancing the requisite science and technology toward achieving these goals.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.